Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge is advising Medivir in connection with its rights issue
Mandate

Vinge is advising Medivir in connection with its rights issue

December 14, 2020 Capital Markets and Public M&A

Vinge is advising Medivir AB (publ) in connection with a rights issue which will provide Medivir with issue proceeds amounting to a maximum of SEK 170 million, as well as with an over-allotment option by way of a directed share issue of a maximum of approximately SEK 25 million.

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients.

Medivir is listed on Nasdaq Stockholm, Small Cap.

Vinge’s team mainly consisted of Dain Hård Nevonen, Amanda Knutsson, Julia Hirschberg and Olof Löfvenberg.

Related

Vinge has advised on the sale of Westcomp AB to Tången Industrikapital AB

 Pursuant to the transaction, Tången acquires approximately 91 per cent of the shares in Westcomp.
October 15, 2025

Vinge has advised Stirling Square Capital Partners (“SSCP”) in connection with the sale of part of its holding in Infobric to KKR

 Pursuant to the transaction, KKR has become a significant owner, while SSCP will remain the largest owner.
October 15, 2025

Vinge advises ABG Sundal Collier in connection with Conapto's issue of subsequent senior secured bonds of SEK 1 billion

 Vinge has advised ABG Sundal Collier in connection with Conapto Holding AB (publ)'s issue of subsequent senior secured bonds of SEK 1 billion, and parallel written procedure to increase the bond framework to SEK 2 billion.
October 15, 2025